Clinical Application of tDCS in Alzheimers Disease

Phase 3

• Conditions: Health Condition 1: F028- Dementia in other diseases classified elsewhere

• Registration Number: CTRI/2023/08/056430
• Lead Sponsor: Department of Health Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 August 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Alzheimer disease diagnosed with NINDCS or DSM 5 criteria with MMSE score more than 16

Exclusion Criteria

1.Participants with unstable medical conditions, serious metabolic and/or cardiac diseases, alcoholism, focal neurological disorders (e.g., epilepsy, stroke, brain injury or tumor) and associated psychiatric disorders

2.Using hypnotics and benzodiazepines up to 2 weeks before the start of the study

3.With any condition (e.g., communication, sensory, or motor deficits) that could significantly interfere with the neuropsychological assessment

4.Exclusion criteria relating to contraindications of neurostimulation will be applied, following the safety guidelines: (a) using psychoactive drugs (b) having implanted metallic or electronic devices; (c) having a cardiac pacemaker, seizures, acute eczema under the electrodes; and (d) the presence of tumors, epilepsy, or substance abuse

Study & Design

• Study Type: Interventional
• Study Design: Not specified